FDA approves subcutaneous injectable for myasthenia gravis
The US Food and Drug Administration (FDA) has given approval to Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with Enhanze for subcutaneous (SC) use for the treatment of generalised myasthenia gravis (gMG). The treatment is approved in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Read More